Literature DB >> 12493178

Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY Antimicrobial Surveillance Program (1997-2000).

Ana C Gales1, Hélio S Sader H, Ronald N Jones.   

Abstract

In spite of the recent medical advances, lower respiratory tract infections are still the most frequent infectious causes of mortality worldwide. The objective of this study was to determine the frequency of occurrence and antimicrobial susceptibility of bacterial isolates collected from hospitalized patients with pneumonia in Latin American medical centers during the first four years of the SENTRY Program. The five most frequently isolated species were (n/%): Pseudomonas aeruginosa (659/26.3%), Staphylococcus aureus (582/23.3%), Klebsiella pneumoniae (255/10.2%), Acinetobacter spp. (239/9.6%), and Enterobacter spp. (134/5.4%). P. aeruginosa demonstrated high rates of resistance to most of the antimicrobials tested. Against P. aeruginosa, the most active agents were meropenem (MIC(50), 1 microg/ml; 71.6% susceptible), amikacin (MIC(50), 4 microg/ml; 71.0% susceptible), and piperacillin/tazobactam (MIC(50), 16 microg/ml; 70.4% susceptible). Imipenem (MIC(50), 1 microg/ml; 84.1% susceptible) and meropenem (MIC(50), 2 microg/ml; 84.9% susceptible) were the most active agents against Acinetobacter spp. followed by tetracycline (MIC(50), </=4 microg/ml; 52.3% susceptible). Although the broad-spectrum cephalosporins had demonstrated excellent in vitro activity against Klebsiella pneumoniae isolates (MIC(50)s range, </= 0.12 to 0.25 microg/ml), elevated rates of resistance (46.3%-58.5%) were observed. Approximately 44.0% and 29.0% of K. pneumoniae and E. coli isolates were considered ESBL producers based on NCCLS criteria, respectively. Overall, the prevalence of methicillin-resistant S. aureus was 46.2%. The most active drugs against this pathogen were vancomycin, teicoplanin, linezolid and quinupristin/dalfopristin. In summary, the SENTRY Antimicrobial Surveillance Program has detected a high prevalence of methicillin-resistant S. aureus and multidrug resistant non-fermentative Gram-negative bacilli isolated from respiratory tract specimens of hospitalized patients with pneumonia in Latin America. Our results emphasize the importance of local surveillance programs in correctly guiding empiric therapy and local intervention programs in attempt to reduce antimicrobial resistance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12493178     DOI: 10.1016/s0732-8893(02)00499-6

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  14 in total

1.  Characterization of the extended-spectrum β-lactamases and determination of the virulence factors of uropathogenic Escherichia coli strains isolated from children.

Authors:  Branka Bedenić; Jasmina Vraneš; Sabine Hofmann-Thiel; Marija Tonkić; Anita Novak; Viljemka Bučević-Popovic; Harald Hoffmann
Journal:  Wien Klin Wochenschr       Date:  2012-08-16       Impact factor: 1.704

2.  Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa.

Authors:  Vincent H Tam; Kai-Tai Chang; Kamilia Abdelraouf; Cristina G Brioso; Magdalene Ameka; Laurie A McCaskey; Jaye S Weston; Juan-Pablo Caeiro; Kevin W Garey
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

Review 3.  Cefepime: a reappraisal in an era of increasing antimicrobial resistance.

Authors:  Andrea Endimiani; Federico Perez; Robert A Bonomo
Journal:  Expert Rev Anti Infect Ther       Date:  2008-12       Impact factor: 5.091

Review 4.  Imipenem resistance of Pseudomonas in pneumonia: a systematic literature review.

Authors:  Marya D Zilberberg; Joyce Chen; Samir H Mody; Andrew M Ramsey; Andrew F Shorr
Journal:  BMC Pulm Med       Date:  2010-08-26       Impact factor: 3.317

5.  Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.

Authors:  Tetsufumi Koga; Nobuhisa Masuda; Masayo Kakuta; Eiko Namba; Chika Sugihara; Takashi Fukuoka
Journal:  Antimicrob Agents Chemother       Date:  2008-06-02       Impact factor: 5.191

6.  Outcomes of critically ill cancer patients with Acinetobacter baumannii infection.

Authors:  Silvio A Ñamendys-Silva; Paulina Correa-García; Francisco J García-Guillén; María O González-Herrera; Américo Pérez-Alonso; Julia Texcocano-Becerra; Angel Herrera-Gómez; Patricia Cornejo-Juárez; Abelardo Meneses-García
Journal:  World J Crit Care Med       Date:  2015-08-04

7.  Nationwide surveillance of antimicrobial resistance among Enterobacteriaceae in intensive care units in Taiwan.

Authors:  S-S Jean; P-R Hsueh; W-S Lee; H-T Chang; M-Y Chou; I-S Chen; J-H Wang; C-F Lin; J-M Shyr; W-C Ko; J-J Wu; Y-C Liu; W-K Huang; L-J Teng; C-Y Liu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-08-21       Impact factor: 3.267

8.  Prevalence and genotypic relatedness of carbapenem resistance among multidrug-resistant P. aeruginosa in tertiary hospitals across Thailand.

Authors:  Piyatip Khuntayaporn; Preecha Montakantikul; Piroon Mootsikapun; Visanu Thamlikitkul; Mullika Traidej Chomnawang
Journal:  Ann Clin Microbiol Antimicrob       Date:  2012-09-13       Impact factor: 3.944

Review 9.  Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options.

Authors:  Ya-Ting Chang; Chun-Yu Lin; Yen-Hsu Chen; Po-Ren Hsueh
Journal:  Front Microbiol       Date:  2015-09-02       Impact factor: 5.640

10.  Drug resistance profile and biofilm forming potential of Pseudomonas aeruginosa isolated from contact lenses in Karachi-Pakistan.

Authors:  Syed H Abidi; Sikandar K Sherwani; Tarrunum R Siddiqui; Asma Bashir; Shahana U Kazmi
Journal:  BMC Ophthalmol       Date:  2013-10-17       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.